A Causal Inference of the Effect of Vaccination on COVID-19 Disease Severity and Need for Intensive Care Unit Admission Among Hospitalized Patients in an African Setting
=========================================================================================================================================================================

* Eskedar Kebede Belayneh
* Tigist Workneh Leulseged
* Blen Solomon Teklu
* Bersabel Hilawi Tewodros
* Muluken Zeleke Megiso
* Edengenet Solomon Weldesenbet
* Mefthe Fikru Berhanu
* Yohannes Shiferaw Shaweno
* Kirubel Tesfaye Hailu

## ABSTRACT

**Background** The COVID-19 pandemic is a respiratory illness that has spread to over 210 countries and killed over 6 million people. There is no specific treatment for COVID-19, but vaccines have been developed that can help prevent severe illness and death. A number of studies have investigated the effect of vaccination on disease severity and outcome, and the findings indicate that vaccination is linked to a significant reduction in the risk of hospitalization, intensive care unit admission, and death from the disease. However, there is a scarcity of evidence in Africa in general, and no similar study has been conducted in Ethiopia yet. Therefore, the study aimed to assess the effect of vaccination on COVID-19 disease severity and need for Intensive Care Unit (ICU) admission among hospitalized patients at a private specialty clinic in Ethiopia.

**Methods** A retrospective cohort study was conducted among 126 patients with COVID-19, 41 vaccinated and 85 unvaccinated, who were hospitalized between September 2021 and May 2022. Data was summarized using frequency (percentage) and median (interquartile range). To compare the characteristics of the two groups, Chi-square/ Fisher’s Exact and Mann Whitney U tests at p-value of ≤ 0.05 were used. To identify the effect of vaccination on COVID-19 disease severity, Marginal Structural Model (MSM) with inverse probability weighting (IPW) approach using robust poisson regression model was fitted and adjusted relative risk (ARR) and 95% CI for ARR were used for interpreting the result.

**Results** The cohort included groups that were fairly comparable in terms of their sociodemographic and clinical characteristics. More than half of the participants were older than 60 years (52.4%), were males (56.3%) and had one or more comorbid illness (52.4%). At admission 85 (67.5%) had severe disease and 11 (8.7%) progressed after hospitalization and required ICU admission, of which three unvaccinated cases died. From the final model, vaccination was found to be associated with a 62% decreased risk of developing severe COVID-19 disease if infected, compared to not getting vaccinated (ARR=0.38, 95% CI=0.23-0.65, p<0.0001).

**Conclusions** The study’s findings support previous reports that vaccinated people are less likely to develop severe COVID-19 disease if infected with the virus, emphasizing the importance of continuing efforts to promote COVID-19 vaccination not only to safeguard individuals but also to confer community-level immunity.

Key words
*   COVID-19
*   Vaccination
*   Retrospective Cohort
*   Causal Inference
*   Ethiopia

## BACKGROUND

COVID-19 is a respiratory illness caused by a virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus was first identified in Wuhan, China, in December 2019. Since then, it has spread to over 210 countries and territories, infecting over 700 million people and killing over 6 million. And in Ethiopia, over 500 thousand confirmed cases and over 7 thousand deaths have been reported so far (1).

There is no specific treatment for COVID-19. Instead, supportive care is the mainstay of treatment, which includes measures such as rest, fluids, and medications to relieve symptoms. In severe cases, patients may need oxygen therapy or mechanical ventilation (2-4). As a more effective strategy, a vaccine to prevent COVID-19 was developed. The first COVID-19 vaccine was approved by the U.S. Food and Drug Administration on August 23, 2021 (5). Since then, millions of people around the world have been vaccinated. As of August 9, 2023, a total of 13,492,264,486 vaccine doses have been administered globally (1). The Ethiopian Federal Ministry of Health launched COVID-19 immunization on March 13, 2021, and as of May 27, 2023, a total of 68,856,793 vaccine doses have been provided (1,6).

While the safety and efficacy of the vaccines have been proven in controlled studies and are expected to reduce morbidity and mortality, there is an irrefutable need for further evidence of the effectiveness of the vaccines in preventing severe illness and death from COVID-19 in the real world (7-21). With this in mind, a number of studies have investigated the effect of COVID-19 vaccination on disease severity and outcome. According to these studies, Vaccination has been linked to a significant reduction in the risk of hospitalization, intensive care unit admission, and death from COVID-19 (22-30). However, there is a scarcity of evidence throughout Africa in general, and in Ethiopia in particular (31-32). Moreover, disease epidemiology in Africa appears to differ from that of the rest of the world thus far (33-40). Given these disparities in disease epidemiology and the lack of adequate evidence, it is especially important to understand the potential changes in disease patterns in the post-vaccination era in a local setting. Findings from such research can be used to make informed decisions at both the public health policy design and individual levels. Therefore, the aim of this study was to assess the effect of vaccination on COVID-19 disease severity and need for ICU admission among hospitalized patients at a private specialty clinic in Ethiopia from September 2021 to May 2022.

## METHODS

### Study Setting and Design

An institution-based retrospective cohort study, following the STROBE checklist for cohort studies, was conducted from June to August, 2023 among COVID-19 patients who were admitted at a private clinic, MuluG health Services, between September 2021 and May 2022. The hospital is a primary Internal Medicine, Gynecology and pediatric specialty center, which had a dedicated ward for COVID-19 patients management during the pandemic. The cohort was classified into two groups based on their vaccination status for COVID-19 as fully/partially vaccinated (exposed group) and unvaccinated (non-exposed group).

### Population and Sample size

The study included all laboratory-confirmed COVID-19 patients who were admitted and completed their follow-up at the hospital between September 2021 and May 2022 and had complete data on basic clinical and laboratory parameters, and COVID-19 vaccination status. Accordingly, from the 184 admissions, 126 eligible participants (41 vaccinated and 85 unvaccinated) were included in the study.

A post-hoc power analysis was calculated using G*Power 3.19.4 to check the power of the study using a two-tailed z-test for difference between two independent proportions with the following statistical parameters; 5% level of significance, proportion of severe COVID-19 and sample size in the vaccinated group of 36.6% and 41, respectively; and proportion of severe COVID-19 and sample size in the non-vaccinated group of 82.4% and 85, respectively. Finally, the power of the study was found to be 99.9%.

### Operational Definitions

*   - **Moderate COVID-19 Disease:** Individuals who show evidence of lower respiratory disease during clinical assessment or imaging and who can maintain oxygenation in room air (2, 4).

*   - **Severe COVID-19 Disease:** Includes patients who have SPO2 ≤ 93% on atmospheric air or a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) (SF ratio < 315), in respiratory distress or respiratory rate >30 breaths/minutes, or lung infiltrates involving >50% of the chest (2, 4).

### Data Collection Procedures and Quality Assurance

Data on socio-demographic, clinical, laboratory and vaccination status of the patients was extracted from the electronic data registry system that was designed using the WHO CRF patient management and follow-up form. Data quality was assured through proper training of two data collectors (General Practitioners) on the tool, double data entry, and data cleaning through checking for inconsistencies, numerical errors and missing parameters. All data management and analysis were performed using STATA software version 17.0 (College Station, TX).

### Statistical Analysis

The study population characteristics was summarized and presented using frequency with percentage for categorical variables. Symptom duration, measured in days, was summarized using median with interquartile range (IQR) due to the skewed distribution of the data (Kolmogorov-Smirnov and Shapiro-Wilk tests p-value <0.0001). To compare the socio-demographic and clinical characteristics within the cohort (Vaccinated Vs Unvaccinated), a Chisquare test was used. Whenever the assumption of a chi-square test where no cell should have expected count of <5 failed, Fisher’s exact test was used instead. To compare the median symptom duration between the groups, a Mann Whitney U test was used. For all tests, a statistically significant difference was detected for variables with a p-value of ≤ 0.05.

To identify the effect of vaccination on COVID-19 disease severity (moderate vs severe), Marginal Structural Model (MSM) with inverse probability weighting (IPW) approach was used in two steps.

First, the treatment model using a binary logistic regression model was run to estimate the probability of vaccination status given the covariates (propensity score). The estimated probability of vaccination status was then used to compute the inverse probability weights for each individual. The inverse of the probability of vaccination was then used to weight each individual in the estimation of the marginal odds ratio. Univariate analysis at 25% level of significance and clinical judgment was used to select variables to be included in the treatment model.

Subsequently, the final outcome model, using the vaccination status variable adjusted for inverse probability weights, was fitted to predict COVID-19 disease severity. To identify the effect of vaccination on disease severity, a Robust Poisson regression model was selected. Fitness of the model was assessed using Pearson chi-square and Deviance tests and the model fit the data well. Accordingly, on the final model, a p-value of ≤ 0.05 indicates that vaccination is a significant predictor of COVID-19 disease severity. In case of significant relationship, adjusted relative risk (ARR) and 95% CI for ARR were used for interpreting the result. Effect of vaccination on need for ICU admission was not assessed due to the small frequency of the outcome.

## RESULTS

### Socio-demographic and Clinical Characteristics

More than half of the participants were older than 60 years (52.4%) and were males (56.3%). The frequent presenting symptom was cough in 119 (94.4%) followed by anorexia in 96 (76.2%), and constitutional symptoms of myalgia in 63 (50.0%), arthralgia in 62 (49.2%), and headache in 51 (40.5%). Anosmia and/or ageusia were reported by 58 (46.0%). The median duration of symptoms was 7 days (IQR, 4-10 days), with a minimum of 1 day and a maximum of 20 days. Sixty-six patients (52.4%) presented with one or more comorbid conditions, with hypertension and diabetes being the most prevalent, affecting 38 patients (30.2%) each. .

According to the Chi-square/Fisher’s exact and Mann Whitney U tests, there was no statistically significant difference in age, sex, presenting symptom, symptom duration or comorbid illness history between vaccinated and unvaccinated patients. (**Table 1**)

View this table:
[Table 1:](http://medrxiv.org/content/early/2023/08/24/2023.08.22.23294414/T1)

Table 1: Socio–demographic and clinical characteristics of COVID-19 patients in Ethiopia (n=126)

### Vital sign and Laboratory Parameters

Upon baseline assessment, only a smaller proportion of patients presented with abnormal vital signs and laboratory parameters. Of these, 21.4% had elevated systolic blood pressure (SBP), 14.3% had elevated diastolic blood pressure (DBP), 32.5% had an elevated pulse rate (PR), and 7.1% had hyperthermia. Furthermore, 27.8% had an elevated neutrophil to lymphocyte ratio (NLR), 57.9% had an elevated hematocrit, 27.0% had a platelet count of less than 150 x 103/ul or greater than 450 x 103/ul, 23.0% had an elevated blood urea nitrogen (BUN) level, and 31.7% had an elevated creatinine level. On the other hand, the majority (71.4%) presented with hypothermia.

Additionally, the result showed that unvaccinated patients were more likely to have a raised pulse rate (38.8% Vs 19.5%, p-value=0.030), and BUN (28.2% Vs 12.2%, p-value=0.045) than vaccinated patients. Otherwise, there were no significant differences between the two groups in terms of their blood pressure, oxygen saturation, temperature, NLR, hematocrit level, platelet count, or creatinine level. (**Table 2**)

View this table:
[Table 2:](http://medrxiv.org/content/early/2023/08/24/2023.08.22.23294414/T2)

Table 2: Vital sign and laboratory parameters of COVID-19 patients in Ethiopia (n=126)

### COVID-19 Disease Severity and Need for ICU Admission

Of the 126 hospitalized COVID-19 patients, 85 (67.5%, 95% CI=59.7-76.8%) had severe disease, while 41 (32.5%, 95% CI= 23.2-40.3%) had moderate disease upon admission.

Disease progression after hospitalization that necessitated ICU care occurred in 11 (8.7%, 95%=4.9-15.2%). One of the 11 cases was vaccinated and was later discharged improved. The remaining ten were unvaccinated, of which seven were discharged improved and three died.

### Treatment model: Logistic regression of factors associated with COVID-19 vaccination

The treatment model using a binary logistic regression model was run by including the following categories: age category, sex, fever, headache, arthralgia, anorexia, anosmia/ageusia, diarrhea, vomiting, nausea, diabetes, hypertension, SBP, DBP, PR, temperature, NLR, hematocrit, platelet, Bun, and creatinine. By fitting the final treatment model, propensity score was estimated and it was used to compute the inverse probability weights for each individual. The inverse of the probability of vaccination status was then used to weight each individual in the estimation of the marginal odds ratio. (**Table 3**)

View this table:
[Table 3:](http://medrxiv.org/content/early/2023/08/24/2023.08.22.23294414/T3)

Table 3: Binary Logistic Regression model of factors associated with vaccination status among COVID-19 patients in Ethiopia (n=126)

### Outcome Model: Effect of vaccination on COVID-19 disease severity

To identify the effect of vaccination on COVID-19 disease severity, a Robust Poisson regression model was run by fitting the vaccination status variable adjusted for inverse probability weights, that was obtained from the treatment model above.

The result shows that vaccination is associated with a 62% decreased risk of developing severe COVID-19 disease if infected, compared to not getting vaccinated **(ARR=0.38, 95% CI=0.23-0.65, p<0.0001)**. (**Table 4**)

View this table:
[Table 4:](http://medrxiv.org/content/early/2023/08/24/2023.08.22.23294414/T4)

Table 4: Robust poisson regression of effect of vaccination on disease severity among COVID-19 patients in Ethiopia (n=126)

## DISCUSSION

This retrospective cohort study investigated the effect of vaccination on COVID-19 disease severity among hospitalized patients who were on follow-up at a private specialty clinic in Ethiopia between September 2021 and May 2022. Although multiple studies are done internationally, this is the first of its kind to answer this research question at an Ethiopian institution. The study included 126 hospitalized COVID-19 patients, 41 vaccinated and 85 unvaccinated. The participants were fairly comparable in terms of their socio-demographic and clinical characteristics. More than half of the participants were older than 60 years (52.4%), were males (56.3%) and had one or more comorbid illness (52.4%). At admission 85 (67.5%) had severe disease and 11 (8.7%) progressed after hospitalization and required ICU admission, of which three unvaccinated cases died.

According to the Robust Poisson regression analysis using the MSM model with the IPW approach, vaccination is causally associated with disease severity and progression in a protective way, with vaccinated people 62% less likely to develop severe COVID-19 disease if infected with the virus. The findings indicate that immunization plays a significant role in preventing the development of severe disease. This is a noteworthy finding, as it suggests that vaccination can help to protect people from the most serious consequences of COVID-19; hospitalization, longterm complications, and even death. Furthermore, it also contributes to the greater goal of reducing overall healthcare costs and preventing the spread of illness. The study’s findings are consistent with the results of other studies that have shown that vaccination is effective in preventing severe COVID-19 in both Africa (31-32) and outside Africa (22-30). Although the study findings note the importance of vaccination in reducing morbidity and mortality, a significant portion of the population in Ethiopia is unvaccinated (1,6). Hence, the importance of vaccination in reducing morbidity and mortality in combination with other preventative measures is a crucial instrument in the fight against COVID-19 and should not be overlooked by the general public.

When interpreting the study findings, bear the following strengths and limitations in mind. The study’s strengths include the fact that it is the first in Ethiopia and one of only a handful in Africa, it was conducted in a hospital setting where a more complete picture of the influence of vaccine on those who are already infected and required admission can be studied, and the causal effect of vaccination was estimated using a causal inference model which can provide strong evidence of causality from observational data. Its limitations are that further investigation of the vaccine effect in terms of type, dose, and period between vaccination and initial symptom could not be made since they were not documented, and the generalizability is limited as it is a single center study.

## CONCLUSION

The study shows that vaccinated people are less likely to develop severe COVID-19 disease if infected with the virus. Its findings are consistent with studies done to answer similar questions during the clinical trials for COVID-19 vaccine development and post-market surveillance, emphasizing the importance of continuing efforts to promote COVID-19 vaccination not only to safeguard individuals but also to confer community-level immunity. We recommend large prospective community and multicenter studies to gain a better understanding of the effect of vaccination on short- and long-term disease outcomes, taking into account the dose and type of vaccine.

## Data Availability

All relevant data are available upon reasonable request from Tigist W. Leulseged, tigdolly{at}gmail.com.

## Declaration

### Ethics approval and consent to participate

The study was conducted after obtaining ethical clearance from Addis Ababa Regional Health Bureau Ethics Review Committee (AARHB-ERC). The AARHB-ERC also waived the need for informed consent as the study used secondary data. Anonymity of the participants was maintained by use of medical record number in the research report. No other personal identifiers of the patients were used in the research report. Access to the collected information was limited to the investigators and confidentiality was maintained throughout the project.

### Consent for publication

Not applicable

### Availability of data and materials

All relevant data are available upon reasonable request from Tigist W. Leulseged, tigdolly{at}gmail.com.

### Competing interests

The authors declare that they have no known competing interests.

### Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

### Authors’ Contribution

EKB and TWL conceived and designed the study. BST, BHT, MZM, ESW, MFB, YSS, and KTH contributed to the conception and design of the study. TWL performed statistical analysis, and drafted the initial manuscript. BST, BHT, MZM, and KTH contributed to the statistical analysis and interpretation of the findings. EKB, ESW, MFB, and YSS revised the manuscript. All authors approved the final version of the manuscript.

## Acknowledgment

The authors would like to thank all individuals involved in the facilitation of extraction of the electronic data.

*   Received August 22, 2023.
*   Revision received August 22, 2023.
*   Accepted August 24, 2023.


*   © 2023, Posted by Cold Spring Harbor Laboratory

This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at [http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)

## REFERENCES

1.  1.WHO Coronavirus (COVID-19) Dashboard, 9 August 2023, [https://covid19.who.int/](https://covid19.who.int/)
    
    

2.  2.Clinical management of COVID-19: living guideline, 15 September 2022. Geneva: World Health Organization; 2022 (WHO/2019-nCoV/Clinical/2022.2). Licence: CC BY-NC-SA 3.0 IGO.
    
    

3.  3.CDC, COVID-19 Treatments and Medications, May 26, 2023, [https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html](https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html)
    
    

4.  4.EFMOH, NATIONAL COMPREHENSIVE COVID19 MANAGEMENT HANDBOOK, FMOH, Ethiopia First edition APRIL 2020, [https://covidlawlab.org/wp-content/uploads/2020/06/National-Comprehensive-COVID19-Management-Handbook.pdf](https://covidlawlab.org/wp-content/uploads/2020/06/National-Comprehensive-COVID19-Management-Handbook.pdf)
    
    

5.  5.U.S. Food and Drug Administration, August 23, 2021, [https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine](https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine)
    
    

6.  6.WHO, Ethiopia introduces COVID-19 vaccine in a national launching ceremony, 13 March 2021, [https://reliefweb.int/report/ethiopia/ethiopia-introduces-covid-19-vaccine-national-launching-ceremony?gclid=Cj0KCQjwuZGnBhD1ARIsACxbAVgUbxMv5YEdtf3AzRmH-5FZkXS3qfeC7WgacD7i3qAtqslMttOrwM4aAs1eEALw\_wcB](https://reliefweb.int/report/ethiopia/ethiopia-introduces-covid-19-vaccine-national-launching-ceremony?gclid=Cj0KCQjwuZGnBhD1ARIsACxbAVgUbxMv5YEdtf3AzRmH-5FZkXS3qfeC7WgacD7i3qAtqslMttOrwM4aAs1eEALw_wcB)
    
    

7.  7. Fernando P. Polack,  Stephen J. Thomas,  Nicholas Kitchin, et al., Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, N Engl J Med 2020; 383:2603–2615 DOI: 10.1056/NEJMoa2034577
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2034577&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33301246&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F24%2F2023.08.22.23294414.atom) 

8.  8.Thomas SJ,  Moreira ED Jr, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021 Nov 4;385(19):1761–1773. doi: 10.1056/NEJMoa2110345. Epub 2021 Sep 15. PMID: 34525277; PMCID: PMC8461570.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2110345&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34525277&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F24%2F2023.08.22.23294414.atom) 

9.  9.Bravo L, Smolenov I, Han HH, et al. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2022;399(10323):461–472. doi:10.1016/S0140-6736(22)00055-1
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S0140-6736(22)00055-1&link_type=DOI) 

10. 10.Moreira ED, Kitchin N, Xu X, et al. Safety and efficacy of a third dose of BNT162b2 COVID-19 vaccine. N Engl J Med. 2022;386(20):1910–1921. doi:10.1056/NEJMoa2200674
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2200674&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=35320659&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F24%2F2023.08.22.23294414.atom) 
    
    Sadoff J, Gray G, Vandebosch A, et al. Final analysis of efficacy and safety of single-dose Ad26. COV2. S. N Engl J Med. 2022;386(9):847–860. doi:10.1056/NEJMoa2117608
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2117608&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=35139271&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F24%2F2023.08.22.23294414.atom) 

11. 11.Hardt K, Vandebosch A, Sadoff J, et al. Efficacy, safety, and immunogenicity of a booster regimen of Ad26. COV2. S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2022;22:1703–1715. doi:10.1016/S1473-3099(22)00506-0
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S1473-3099(22)00506-0&link_type=DOI) 

12. 12.Madhi SA, Moodley D, Hanley S, et al. Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, Phase 2A/2B trial. Lancet HIV. 2022;9(5):e309–e322. doi:10.1016/S2352-3018(22)00041-8
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S2352-3018(22)00041-8&link_type=DOI) 

13. 13.Madhi SA, Koen AL, Izu A, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV. 2021;8(9):e568–e580. doi:10.1016/S2352-3018(21)00157-0
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/S2352-3018(21)00157-0&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34416193&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F24%2F2023.08.22.23294414.atom) 

14. 14.Zhang Y, Belayachi J, Yang Y, et al. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco. medRxiv. 2022;22:1584.
    
    

15. 15.Hammad NM, Kadry HM, Malek MM, et al. Maintenance of antibody response in Egyptian healthcare workers vaccinated with ChAdOx1 nCoV-19 vaccine during delta and omicron variants pandemic: a prospective study. Vaccines. 2022;10(10):1706. doi:10.3390/vaccines10101706
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3390/vaccines10101706&link_type=DOI) 

16. 16.Takuva S, Takalani A, Seocharan I, et al. Safety evaluation of the single-dose Ad26. COV2. S vaccine among healthcare workers in the Sisonke study in South Africa: a Phase 3b implementation trial. PLoS Med. 2022;19(6):e1004024. doi:10.1371/journal.pmed.1004024
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pmed.1004024&link_type=DOI) 

17. 17.Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant. N Engl J Med. 2021;384 (20):1885–1898. doi:10.1056/NEJMoa2102214
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2102214&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33725432&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F24%2F2023.08.22.23294414.atom) 

18. 18.Gray G, Collie S, Goga A, et al. Effectiveness of Ad26. COV2. S and BNT162b2 vaccines against Omicron variant in South Africa. N Engl J Med. 2022;386:2243–2245. doi:10.1056/NEJMc2202061
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMc2202061&link_type=DOI) 

19. 19.Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B. 1.351 variant. N Engl J Med. 2021;384 (20):1899–1909. doi:10.1056/NEJMoa2103055
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2103055&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=33951374&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F24%2F2023.08.22.23294414.atom) 

20. 20.Mengstu S, Beyene Berha A. Safety and Efficacy of COVID-19 Vaccine in Africa: Systematic Review. Infect Drug Resist. 2023 May 18;16:3085–3100. doi: 10.2147/IDR.S401074. PMID: 37222988; PMCID: PMC10202204.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.2147/IDR.S401074&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=37222988&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F24%2F2023.08.22.23294414.atom) 

21. 21.Who, Who COVID-19 death prediction, 02 June 2022, [https://www.afro.who.int/news/covid-19-deaths-african-region-fall-nearly-94-2022-who-analysis](https://www.afro.who.int/news/covid-19-deaths-african-region-fall-nearly-94-2022-who-analysis)
    
    

22. 22.de Gier B, van Asten L, Boere TM, van Roon A, van Roekel C, Pijpers J, van Werkhoven CHH, van den Ende C, Hahné SJM, de Melker HE, Knol MJ, van den Hof S. Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other causes, the Netherlands, January 2021-January 2022. Vaccine. 2023 Jul 12;41(31):4488–4496. doi: 10.1016/j.vaccine.2023.06.005. Epub 2023 Jun 8. PMID: 37328352; PMCID: PMC10247887.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1016/j.vaccine.2023.06.005&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=37328352&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F24%2F2023.08.22.23294414.atom) 

23. 23.Mehta RM, Bansal S, Satish V, Amoghvarsha V, Kalpakam H. Impact of COVID-19 vaccination on disease severity & outcomes in hospitalized patients in a tertiary care centre in the second wave. Indian J Med Res. 2022 May-Jun;155(5&6):496–498. doi: 10.4103/ijmr.ijmr\_2232\_21. PMID: 36348596; PMCID: PMC9807189.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access\_num=10.4103/ijmr.ijmr_2232_21&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=36348596&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F24%2F2023.08.22.23294414.atom) 

24. 24.Stepanova, M., Lam, B., Younossi, E. et al. The impact of variants and vaccination on the mortality and resource utilization of hospitalized patients with COVID-19. BMC Infect Dis 22, 702 (2022). doi:10.1186/s12879-022-07657-z
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s12879-022-07657-z&link_type=DOI) 

25. 25. Rahmani Kazem,  Shavaleh Rasoul,  Forouhi Mahtab, et al., The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis, Frontiers in Public Health, 10, 2022,[https://www.frontiersin.org/articles/10.3389/fpubh.2022.873596](https://www.frontiersin.org/articles/10.3389/fpubh.2022.873596), DOI=10.3389/fpubh.2022.873596
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.3389/fpubh.2022.873596&link_type=DOI) 

26. 26.Tenforde MW, Self WH, Adams K, et al. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA. 2021;326(20):2043–2054. doi:10.1001/jama.2021.19499
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2021.19499&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34734975&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F24%2F2023.08.22.23294414.atom) 

27. 27. Nick Andrews,  Elise Tessier,  Julia Stowe, et al., Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines, N Engl J Med 2022; 386:340–350 DOI: 10.1056/NEJMoa2115481
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1056/NEJMoa2115481&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=35021002&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F24%2F2023.08.22.23294414.atom) 

28. 28. Ibrahim Mohammed,  Areej Nauman,  Pradipta Paul,  Sanjith Ganesan,  Kuan-Han Chen,  Syed Muhammad Saad Jalil,  Shahd H. Jaouni,  Hussam Kawas,  Wafa A. Khan,  Ahamed Lazim Vattoth,  Yasmeen Alavi Al-Hashimi,  Ahmed Fares,  Rached Zeghlache &  Dalia Zakaria (2022) The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review, Human Vaccines & Immunotherapeutics, 18:1, DOI: 10.1080/21645515.2022.2027160
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1080/21645515.2022.2027160&link_type=DOI) 

29. 29.Baker, T.B., Bolt, D.M., Smith, S.S. et al. The Relationship of COVID-19 Vaccination with Mortality Among 86,732 Hospitalized Patients: Subpopulations, Patient Factors, and Changes over Time. J GEN INTERN MED 38, 1248–1255 (2023). doi:10.1007/s11606-022-08007-0
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s11606-022-08007-0&link_type=DOI) 

30. 30.Andrews, A., C. Mathew, A., & Mathew, T. (2023). COVID-19 vaccination status and its effect on outcome and disease severity. International Journal Of Community Medicine And Public Health, 10(2), 629–634. doi:10.18203/2394-6040.ijcmph20230016
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.18203/2394-6040.ijcmph20230016&link_type=DOI) 

31. 31. Andreas Chiabi,  Princewill Kum Unji,  Alex Mambap Tatang, et al., COVID-19 Vaccination: Impact on Disease Severity and Mortality in an African Setting, Academic Journal of Health Sicences, 2023/38 (3): 142–147, [https://ibdigital.uib.es/greenstone/sites/localsite/collect/medicinaBalear/index/assoc/AJHS_M](https://ibdigital.uib.es/greenstone/sites/localsite/collect/medicinaBalear/index/assoc/AJHS_M) ed/icina\_Ba/lear\_202/3v38n3p1/42.dir/AJHS\_Medicina\_Balear_2023v38n3p142.pdf
    
    

32. 32. Duncan Chanda,  Jonas Z Hines,  Megumi Itoh, et al., COVID-19 Vaccine Effectiveness Against Progression to In-Hospital Mortality in Zambia, 2021–2022, Open Forum Infectious Diseases, Volume 9, Issue 9, September 2022, ofac469, doi:10.1093/ofid/ofac469
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1093/ofid/ofac469&link_type=DOI) 

33. 33.Leulseged TW, Alemahu DG, Hassen IS, Maru EH, Zewde WC, Chamiso NW, Yegele KT, Abebe DS, Abdi FM, Minyelshewa EY, Gerbi TG, Hagos HT. Factors associated with development of symptomatic disease in Ethiopian COVID-19 patients: a case-control study. BMC Infect Dis. 2021 Aug 5;21(1):759. doi: 10.1186/s12879-021-06465-1. PMID: 34353283; PMCID: PMC8339680.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1186/s12879-021-06465-1&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34353283&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F24%2F2023.08.22.23294414.atom) 

34. 34.Abayomi A, Odukoya O, Osibogun A, Wright O, Adebayo B, Balogun M, et al. Presenting Symptoms and Predictors of Poor Outcomes Among 2,184 Patients with COVID-19 in Lagos State, Nigeria. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2021;102:226–32.
    
    

35. 35.Leulseged TW, Abebe KG, Hassen IS, Maru EH, Zewde WC, Chamiso NW, Yegele KT, Bayisa AB, Siyoum DF, Edo MG, Mesfin EG, Derejie MN, Shiferaw HK. COVID-19 disease severity and associated factors among Ethiopian patients: A study of the millennium COVID-19 care center. PLoS One. 2022 Jan 27;17(1):e0262896. doi: 10.1371/journal.pone.0262896. PMID: 35085338; PMCID: PMC8794201.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1371/journal.pone.0262896&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=35085338&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F24%2F2023.08.22.23294414.atom) 

36. 36.Abraha HE, Gessesse Z, Gebrecherkos T, Kebede Y, Weldegiargis AW, Tequare MH, et al. Clinical features and risk factors associated with morbidity and mortality among patients with COVID-19 in northern Ethiopia. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2021;105:776–83.
    
    

37. 37.Nachega JB, Ishoso DK, Otokoye JO, Hermans MP, Machekano RN, Sam-Agudu NA, et al. Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo, Am J Trop Med Hyg. 2020;103(6):2419–2428.
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=http://www.n&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F24%2F2023.08.22.23294414.atom) 

38. 38.Leulseged TW, Maru EH, Hassen IS, Zewde WC, Chamiso NW, Abebe DS, Jagema TB, Banegyisa AB, Gezahegn MA, Tefera OS, Shiferaw WG, Admasu TT. Predictors of death in severe COVID-19 patients at millennium COVID-19 care center in Ethiopia: a case-control study. Pan Afr Med J. 2021 Apr 12;38:351. doi: 10.11604/pamj.2021.38.351.28831. PMID: 34367430; PMCID: PMC8308857.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.11604/pamj.2021.38.351.28831&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=34367430&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F24%2F2023.08.22.23294414.atom) 

39. 39.Elimian KO, Ochu CL, Ebhodaghe B, Myles P, Crawford EE, Igumbor E, et al. Patient characteristics associated with COVID-19 positivity and fatality in Nigeria: retrospective cohort study. BMJ Open. 2020;10(12):e044079.
    
    [Abstract/FREE Full Text](http://medrxiv.org/lookup/ijlink/YTozOntzOjQ6InBhdGgiO3M6MTQ6Ii9sb29rdXAvaWpsaW5rIjtzOjU6InF1ZXJ5IjthOjQ6e3M6ODoibGlua1R5cGUiO3M6NDoiQUJTVCI7czoxMToiam91cm5hbENvZGUiO3M6NzoiYm1qb3BlbiI7czo1OiJyZXNpZCI7czoxMzoiMTAvMTIvZTA0NDA3OSI7czo0OiJhdG9tIjtzOjUwOiIvbWVkcnhpdi9lYXJseS8yMDIzLzA4LzI0LzIwMjMuMDguMjIuMjMyOTQ0MTQuYXRvbSI7fXM6ODoiZnJhZ21lbnQiO3M6MDoiIjt9) 

40. 40.Leulseged TW, Hassen IS, Maru EH, Zewde WC, Chamiso NW, Edo MG, Abebe DS, Aliy MA. COVID-19 in hospitalized Ethiopian children: characteristics and outcome profile. Pan Afr Med J. 2022 Jan 7;41:16. doi: 10.11604/pamj.2022.41.16.29414. PMID: 35291361; PMCID: PMC8895553.
    
    [CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.11604/pamj.2022.41.16.29414&link_type=DOI) 
    
    [PubMed](http://medrxiv.org/lookup/external-ref?access_num=35291361&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2023%2F08%2F24%2F2023.08.22.23294414.atom)